Press Room

Event

2017 CPhI Worldwide

Start
Tuesday, October 24, 2017 - 08:00
End
Thursday, October 26, 2017 - 18:00
Location: Frankfurt, Germany
Booth Number: 111F21

Hovione will be attending CPhI Worldwide 2017 in Frankfurt, Germany. An event that is considered the world's leading European pharmaceutical exhibition, which brings together more than 42,000 pharma industry professionals from 150+ countries.

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Our team will be pleased to meet you.

 

the leader in spray drying | Hovione
/products-and-services/contract-manufacturing-services/particle-engineering/tec…

Hovione, the Leader in Spray Drying



Combining the largest capacity, the best scale-up science and the most experienced team, you can trust Hovione to take your project from development to market.

  • Hovione offers a number of innovative Particle Engineering technologies, at all scales, to address challenges in drug delivery.
  • More than 13 years of expertise in commercial Spray Drying.
API Plus products | Hovione

API+

Enabling Novel Formulations Through Engineered Drug Product Intermediate

  • Targeted lung delivery
  • Taste masking
  • Controlled release
  • Modified solubility
  • Improved stability
  • Nanoparticles

The Experts in Customized API for Inhalation

Hovione is using its advanced technologies to enhance API's performance and offer a range of customized Drug Product Intermediates.

Hovione inhalation grade APIs are designed at the particle level to bring unique performance to your formulation.



hovione-customized-apis-for-inhalation



Hovione provides the peace of mind of a high quality manufacturer who is a founding member of Rx-360 and has an unblemished regulatory track record.

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Our team will be pleased to meet you.

We look forward to meeting you at our booth # 111F21 at the Messe Frankfurt in Germany.

 

 

 

You might be also interested in:

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping
News Medical Life Sciences, 1 June 2026

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026

Every year, the largest bank in Portugal, Caixa Geral de Depósitos recognizes some of Portugal’s brightest young minds through the Caixa +Mundo Awards, providing nearly €800,000 in scholarships to students as they pursue higher education. In this year´s edition, Caixa named the award bestowed upon students pursuing science for Diane Villax. This prestigious honor places Diane Villax among the award’s namesakes – a distinguished group of prominent personalities who have made notable contributions to Portugal´s socio-economic, cultural, political and scientific development over the last 50 years, such as António Ramalho Eanes, Mário Soares, José Saramago, Sophia de Mello Breyner, Leonor Beleza, Elvira Fortunato, Rui Nabeiro, Américo Amorim, and José Manuel de Mello. Diane Villax will also honor the seven scientific award winners by personally meeting with each of them, and following their journeys as future innovators and leaders. But this honor is about far more than one individual. It is a celebration of an entire organization and the people behind it. For 67 years, generations of dedicated teams have worked together with passion, purpose, and excellence to manufacture life-saving medicines and advance science that has a real impact on people. This recognition belongs to all of us.    

News

Prestigious Caixa +Mundo Award named in honor of Diane Villax

May 14, 2026

CDMO Hovione and Industrial Design Consultancy (IDC) have announced that their new single-use capsule-based nasal delivery device is now available exclusively as part of an integrated platform that includes Hovione’s intranasal drug development and manufacturing services. The companies partnered in 2023 with plans for development of two capsule-based devices for intranasal delivery: the single-use device and a multidose device. Read the full article at OINDPnews.com      

Press Clipping
OINDP - Orally inhaled and nasal drug products news, May 11, 2026

Hovione and IDC announce new single-use capsule-based intranasal delivery device for dry powder formulations

May 11, 2026

Also in Events

See All